Compare NICM & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NICM | ONCY |
|---|---|---|
| Founded | N/A | 1998 |
| Country | Canada | Canada |
| Employees | 25 | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 109.1M |
| IPO Year | N/A | 2002 |
| Metric | NICM | ONCY |
|---|---|---|
| Price | $6.14 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 1.9K | ★ 661.5K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.32 | $0.73 |
| 52 Week High | $7.00 | $1.51 |
| Indicator | NICM | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 37.34 |
| Support Level | $6.40 | N/A |
| Resistance Level | $6.88 | $0.89 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 26.67 | 0.00 |
Nicola Mining Inc is a junior exploration and custom milling company that is engaged in the business of identification, acquisition, and exploration of mineral property interests, together with custom milling partnerships at its Merritt Mill. The company holds interests in various claims at the following properties: the Treasure Mountain Property, New Craigmont Property, and Dominion Creek Property. Its portfolio of producing assets and development projects is mainly composed of copper, gold, and silver properties spread across British Columbia, Canada.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.